Mostrar el registro sencillo

dc.contributor.authorLópez López, Carlos 
dc.contributor.authorCalvo, Mariona
dc.contributor.authorCámara, Juan Carlos
dc.contributor.authorGarcía-Paredes, Beatriz
dc.contributor.authorGómez-Martín, Carlos
dc.contributor.authorLópez, Ana María
dc.contributor.authorPazo-Cid, Roberto
dc.contributor.authorSastre, Javier
dc.contributor.authorYaya, Ricardo
dc.contributor.authorFeliu, Jaime
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-10-23T14:09:32Z
dc.date.available2024-10-23T14:09:32Z
dc.date.issued2024
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.urihttps://hdl.handle.net/10902/34332
dc.description.abstractHepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.es_ES
dc.description.sponsorshipAcknowledgements: The authors thank Dr Angela Lamarca (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) and Dr Roberto Díaz Beveridge (Hospital Universitario y Politécnico la Fe, Valencia, Spain) for the review of the guidelines and validation of the level of evidence and grade of recommendations.es_ES
dc.format.extent12 p.es_ES
dc.language.isoenges_ES
dc.publisherSpringer-Verlag Italiaes_ES
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceClinical and Translational Oncology, 2024, 26, 2800-2811es_ES
dc.subject.otherHepatocellular carcinomaes_ES
dc.subject.otherGuidelineses_ES
dc.subject.otherDiagnostices_ES
dc.subject.otherStaginges_ES
dc.subject.otherTreatmentes_ES
dc.titleSEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1007/s12094-024-03568-4
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.Excepto si se señala otra cosa, la licencia del ítem se describe como This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.